SecBot SecBot
SECBOTREPLAY Home › Report › TLX

TLX · Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine…

Telix Pharmaceuticals Ltd · 6-K filed Sep 14, 2026 at 16:52 ET

At the news

BULLISHIMPACT 8/10

6-K filed Sep 14, 2026 at 16:52 ET

Telix Pharmaceuticals announced FDA approval of Pixclara (floretyrosine F 18), the first FDA-approved FET-PET imaging drug for glioma (brain cancer). This is a transformative regulatory milestone that opens a new commercial product line in a large, underserved U.S. market (~24,000 new glioma cases/year) and reinforces Telix's leadership in theranostics. The approval is a clear, material positive catalyst for the stock.

  • FDA approved Pixclara (floretyrosine F 18) for PET imaging to differentiate recurrent/progressive glioma from treatment-related change in adults and pediatric patients 1 month+
  • Pixclara is the first and only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer)
  • Approximately 24,000 new glioma cases are diagnosed annually in the U.S., representing a significant addressable market
  • FET-PET imaging is recommended in international clinical practice guidelines, including NCCN Guidelines

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access